Current Report Filing (8-k)
December 30 2016 - 8:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 25, 2016
pSivida Corp.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51122
|
|
26-2774444
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
480 Pleasant Street
Watertown, MA
|
|
02472
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617) 926-5000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.02. Termination of a Material Definitive Agreement.
As of December 26, 2016, the Amended and Restated Collaborative Research and License Agreement, dated June 14, 2011 (the
Restated Agreement), by and among pSivida Corp., pSivida US, Inc., pSiMedica Limited (collectively, the Company) and Pfizer Inc. (Pfizer) automatically terminated pursuant to the terms thereof.
As previously disclosed, the Restated Agreement amended and restated the Collaborative Research and License Agreement, dated as of
April 3, 2007, between the Company and Pfizer (the Original Agreement). Under the Restated Agreement, the Company granted Pfizer an exclusive option under various circumstances to a license to develop and commercialize worldwide a
sustained release bioerodible implant designed to deliver latanoprost by subconjunctival injection (the Product) for ophthalmic diseases in humans other than Uveitis. In exchange, the Company was entitled to consideration of up to $168.8
million plus royalties, regained all rights to its intellectual property in ophthalmic applications previously included in the Original Agreement other than pursuant to the Restated Agreement and had rights to develop and commercialize the Product
if Pfizer were to not exercise its option to do so. In June 2011, Pfizer paid the Company $2.3 million as an upfront payment.
Pursuant to
Section 3.3 of the Restated Agreement, the Company is permitted to elect to cease development of the Product at any time after June 14, 2012 but prior to completion of Phase II clinical trials for the Product, upon providing notice to
Pfizer of such election (the Cessation Notice), at which time the Company would have no further obligations with respect to the Product under the Restated Agreement. After receipt of the Cessation Notice, Pfizer has the right to elect to
solely fund further development and commercialization of the Product, provided that Pfizer is required to make such election and notify the Company (the Funding Option Notice) no later than sixty days after receiving the Cessation
Notice. In the event Pfizer does not submit a Funding Option Notice with respect to the Product within the sixty-day election period, then the Restated Agreement automatically terminates at the end of the sixty-day election period. After such
termination, the Company would have the right, alone or with or through other persons with rights to Pfizer intellectual property necessary to develop, manufacture and commercialize the Product. Notwithstanding the foregoing, if the Company provides
the Cessation Notice but does not actually cease all development activities with respect to the Product for at least one year, then the automatic termination would be null and void and the Restated Agreement would remain in effect.
The Company delivered the Cessation Notice to Pfizer on October 27, 2016. Pursuant to the Restated Agreement, Pfizer had until
December 26, 2016 to deliver a Funding Option Notice to the Company. Pfizer did not provide the Funding Option Notice as of December 26, 2016 and therefore, subject to the limited exception set forth above, the Restated Agreement
automatically terminated as of such date.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed, on December 12, 2016, pSivida Corp. (the
Company) eliminated the position of Vice President of Corporate Affairs and General Counsel, thereby resulting in the termination of Lori Freedman, the Companys Vice President of Corporate Affairs, General Counsel and Company
Secretary, effective as of December 26, 2016. On December 25, 2016, the Company and Ms. Freedman entered into a cooperation agreement, pursuant to which Ms. Freedman will reasonably cooperate with the Company and its subsidiaries
and affiliates for up to 20 hours in each of January and February 2017 regarding all matters for which Ms. Freedman has knowledge of, was involved in or handled in her former role as Vice President of Corporate Affairs and General Counsel. In
exchange for her cooperation, the Company extended the exercise period of all of Ms. Freedmans vested stock options to purchase common stock of the Company to June 26, 2018.
The foregoing description of the cooperation agreement is not complete and is qualified in its entirety by reference to the agreement, which
is filed as Exhibit 10.1 hereto and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
|
|
|
10.1
|
|
Cooperation Agreement, dated December 25, 2016, by and between pSivida Corp. and Lori Freedman.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
pSivida Corp.
|
|
|
|
|
Date: December 30, 2016
|
|
|
|
By:
|
|
/s/ Nancy Lurker
|
|
|
|
|
Name:
|
|
Nancy Lurker
|
|
|
|
|
Title
|
|
President and Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Document
|
|
|
10.1
|
|
Cooperation Agreement, dated December 25, 2016, by and between pSivida Corp. and Lori Freedman.
|
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Sep 2023 to Sep 2024